|
US8183344B2
(en)
*
|
1996-04-24 |
2012-05-22 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
MXPA05010773A
(es)
|
2003-04-09 |
2005-12-12 |
Neose Technologies Inc |
Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
WO2005055930A2
(en)
*
|
2003-12-03 |
2005-06-23 |
University Of Rochester |
Recombinant factor viii having increased specific activity
|
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
|
US7338933B2
(en)
|
2004-01-08 |
2008-03-04 |
Neose Technologies, Inc. |
O-linked glycosylation of peptides
|
|
EP1771066A2
(en)
|
2004-07-13 |
2007-04-11 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
|
|
EP3061461A1
(en)
|
2004-10-29 |
2016-08-31 |
ratiopharm GmbH |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
|
ES2449195T3
(es)
|
2005-01-10 |
2014-03-18 |
Ratiopharm Gmbh |
Factor estimulante de colonias de granulocitos glicopegilado
|
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
|
CA2604299A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Csl Behring Gmbh |
Modified coagulation factor viii with enhanced stability and its derivates
|
|
EP2975135A1
(en)
|
2005-05-25 |
2016-01-20 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
CA2632714A1
(en)
|
2005-12-07 |
2007-06-14 |
Technische Universitaet Muenchen |
Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
|
|
US20090203077A1
(en)
*
|
2006-06-30 |
2009-08-13 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
|
US20080070251A1
(en)
*
|
2006-06-30 |
2008-03-20 |
Kaufman Randal J |
Method of Producing Factor VIII Proteins by Recombinant Methods
|
|
US20080280818A1
(en)
|
2006-07-21 |
2008-11-13 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
|
KR101389376B1
(ko)
|
2007-02-23 |
2014-04-29 |
에스케이케미칼주식회사 |
제 ８ 인자 및 그의 유도체의 제조 및 정제 방법
|
|
ES2406267T3
(es)
|
2007-04-03 |
2013-06-06 |
Biogenerix Ag |
Métodos de tratamiento usando G-CSF glicopegilado
|
|
CN101778859B
(zh)
|
2007-06-12 |
2014-03-26 |
诺和诺德公司 |
改良的用于生产核苷酸糖的方法
|
|
BRPI0818913A2
(pt)
*
|
2007-11-01 |
2015-05-12 |
Univ Rochester |
Fator viii recombinante tendo elevada estabilidade
|
|
JP5647899B2
(ja)
*
|
2008-01-08 |
2015-01-07 |
ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ |
オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
|
|
RU2573587C2
(ru)
|
2008-02-27 |
2016-01-20 |
Ново Нордиск А/С |
Конъюгированные молекулы фактора viii
|
|
KR20160018860A
(ko)
*
|
2008-05-16 |
2016-02-17 |
바이엘 헬스케어 엘엘씨 |
표적화 응고 인자 및 그의 사용 방법
|
|
MX362028B
(es)
|
2009-02-03 |
2019-01-04 |
Amunix Pharmaceuticals Inc |
Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
|
|
CN102741422B
(zh)
|
2009-08-24 |
2016-06-08 |
阿穆尼克斯运营公司 |
凝血因子ⅶ组合物及其制备和使用方法
|
|
CA2776503C
(en)
|
2009-10-02 |
2020-07-28 |
The Children's Hospital Of Philadelphia |
Compositions and methods for enhancing coagulation factor viii function
|
|
EA038618B1
(ru)
|
2009-12-06 |
2021-09-23 |
Биовератив Терапьютикс Инк. |
Химерные и гибридные полипептиды фактора viii-fc и способы их применения
|
|
US9611310B2
(en)
|
2010-07-09 |
2017-04-04 |
Bioverativ Therapeutics Inc. |
Systems for factor VIII processing and methods thereof
|
|
EP3560962A1
(en)
|
2010-07-09 |
2019-10-30 |
Bioverativ Therapeutics Inc. |
Processable single chain molecules and polypeptides made using same
|
|
SG190136A1
(en)
|
2010-11-05 |
2013-07-31 |
Baxter Int |
A new variant of antihemophilic factor viii having increased specific activity
|
|
DK2717898T3
(en)
|
2011-06-10 |
2019-03-25 |
Bioverativ Therapeutics Inc |
COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF
|
|
RS58578B1
(sr)
|
2011-07-08 |
2019-05-31 |
Bioverativ Therapeutics Inc |
Faktor viii himernih i hibridnih polipeptida i postupci za njihovu upotrebu
|
|
EA028914B1
(ru)
|
2011-07-25 |
2018-01-31 |
Байоджен Хемофилия Инк. |
Исследования для мониторинга нарушений свертываемости крови
|
|
CA2850579A1
(en)
*
|
2011-10-18 |
2013-04-25 |
Carsten Horn |
Method for improving the stability of purified factor viii after reconstitution
|
|
CN103889445A
(zh)
|
2011-10-18 |
2014-06-25 |
德国杰特贝林生物制品有限公司 |
硫酸化糖胺聚糖用于改善因子viii的生物利用度的用途
|
|
CN103889446B
(zh)
|
2011-10-18 |
2017-03-08 |
德国杰特贝林生物制品有限公司 |
硫酸化糖胺聚糖与透明质酸酶组合用于改善因子viii的生物利用度
|
|
PT2804623T
(pt)
|
2012-01-12 |
2019-11-18 |
Bioverativ Therapeutics Inc |
Polipéptidos quiméricos do fator viii e suas utilizações
|
|
PL2802668T3
(pl)
|
2012-01-12 |
2019-03-29 |
Bioverativ Therapeutics Inc. |
Sposoby zmniejszania immunogenności wobec czynnika krzepnięcia viii u pacjentów poddawanych leczeniu czynnikiem krzepnięcia viii
|
|
HRP20190454T1
(hr)
|
2012-02-15 |
2019-05-03 |
Bioverativ Therapeutics Inc. |
Rekombinantni faktor viii proteini
|
|
HUE046848T2
(hu)
|
2012-02-15 |
2020-03-30 |
Bioverativ Therapeutics Inc |
VIII. faktor készítmények és eljárások elõállításukra és alkalmazásukra
|
|
EP2858659B1
(en)
|
2012-06-08 |
2019-12-25 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
|
JP2015525222A
(ja)
|
2012-06-08 |
2015-09-03 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
キメラ性凝固因子
|
|
EP3404105A1
(en)
|
2012-07-06 |
2018-11-21 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
|
KR101395736B1
(ko)
*
|
2012-07-10 |
2014-05-16 |
아주대학교산학협력단 |
인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
|
|
NZ703366A
(en)
|
2012-07-11 |
2018-03-23 |
Amunix Operating Inc |
Factor viii complex with xten and von willebrand factor protein, and uses thereof
|
|
HK1212882A1
(zh)
|
2012-07-25 |
2016-06-24 |
Bioverativ Therapeutics Inc. |
血液因子的監測分析及其用途
|
|
AU2013331000B2
(en)
|
2012-10-18 |
2018-04-19 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
|
EP2914293A4
(en)
|
2012-10-30 |
2016-04-20 |
Biogen Ma Inc |
METHOD OF USE OF FVIII POLYPEPTIDE
|
|
SI3889173T1
(sl)
|
2013-02-15 |
2023-11-30 |
Bioverativ Therapeutics Inc. |
Optimiran gen dejavnika VIII
|
|
US10588949B2
(en)
|
2013-03-15 |
2020-03-17 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptide formulations
|
|
SG11201505924TA
(en)
|
2013-03-15 |
2015-09-29 |
Biogen Ma Inc |
Factor viii polypeptide formulations
|
|
ES2657291T3
(es)
|
2013-04-22 |
2018-03-02 |
Csl Ltd. |
Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
|
|
CN105392495A
(zh)
|
2013-06-28 |
2016-03-09 |
比奥根Ma公司 |
具有xten的凝血酶可裂解连接子和其用途
|
|
EP3043813B1
(en)
|
2013-08-08 |
2021-01-13 |
Bioverativ Therapeutics Inc. |
Purification of chimeric fviii molecules
|
|
EP3033097B1
(en)
|
2013-08-14 |
2021-03-10 |
Bioverativ Therapeutics Inc. |
Factor viii-xten fusions and uses thereof
|
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
|
ES2967617T3
(es)
|
2013-12-06 |
2024-05-03 |
Bioverativ Therapeutics Inc |
Herramientas de farmacocinética poblacional y sus usos
|
|
SI4176894T1
(sl)
|
2014-01-10 |
2024-07-31 |
Bioverativ Therapeutics Inc. |
Himerni proteini faktorja VIII in njihova uporaba
|
|
WO2015107222A1
(en)
*
|
2014-01-20 |
2015-07-23 |
Octapharma Ag |
A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
|
|
AU2015214245B2
(en)
|
2014-02-04 |
2020-09-10 |
Biogen Ma Inc. |
Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
|
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
|
CN106687126B
(zh)
|
2014-08-04 |
2020-07-28 |
杰特有限公司 |
因子viii制剂
|
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
|
WO2016142288A1
(en)
|
2015-03-06 |
2016-09-15 |
Csl Behring Recombinant Facility Ag |
Modified von willebrand factor having improved half-life
|
|
JP6651548B2
(ja)
|
2015-05-22 |
2020-02-19 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
改変フォン・ヴィルブランド因子を製造するための方法
|
|
WO2016188907A1
(en)
|
2015-05-22 |
2016-12-01 |
Csl Behring Recombinant Facility Ag |
Truncated von willebrand factor polypeptides for treating hemophilia
|
|
US10745680B2
(en)
|
2015-08-03 |
2020-08-18 |
Bioverativ Therapeutics Inc. |
Factor IX fusion proteins and methods of making and using same
|
|
WO2017050820A1
(en)
*
|
2015-09-22 |
2017-03-30 |
Novo Nordisk A/S |
Fviii fusion proteins
|
|
CA3005565A1
(en)
|
2015-11-13 |
2017-05-18 |
Baxalta Incorporated |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
|
SG11201804070XA
(en)
|
2015-11-13 |
2018-06-28 |
Baxalta Inc |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
|
BR112018013861A2
(pt)
|
2016-01-07 |
2018-12-18 |
Csl Behring Recombinant Facility Ag |
polipeptídeo, complexo, composição farmacêutica, métodos para tratar um distúrbio de coagulação sanguínea, para produzir um polipeptídeo e um dímero de um polipeptídeo, para aumentar a meia vida do fator viii e para aumentar a dimerização do dito polipeptídeo, uso de um polipeptídeo, kit farmacêutico, plasmídeo ou vetor, e, célula hospedeira
|
|
SG10201913278PA
(en)
|
2016-02-01 |
2020-02-27 |
Bioverativ Therapeutics Inc |
Optimized factor viii genes
|
|
EP3476860A4
(en)
|
2016-06-24 |
2020-01-22 |
Mogam Institute for Biomedical Research |
Recombinant single-chain fviii and chemical conjugate thereof
|
|
US11046749B2
(en)
|
2016-06-24 |
2021-06-29 |
Mogam Institute For Biomedical Research |
Chimera protein comprising FVIII and vWF factors, and use thereof
|
|
JP6351679B2
(ja)
*
|
2016-09-30 |
2018-07-04 |
エスケー ケミカルズ カンパニー リミテッド |
第ｖｉｉｉ因子とその誘導体の製造及び精製方法
|
|
TW201828975A
(zh)
|
2016-11-11 |
2018-08-16 |
瑞士商Ｃｓｌ貝林重組技能公司 |
用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
|
|
TW201828974A
(zh)
|
2016-11-11 |
2018-08-16 |
瑞士商Ｃｓｌ貝林重組技能公司 |
用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
|
|
MA46968A
(fr)
|
2016-12-02 |
2019-10-09 |
Bioverativ Therapeutics Inc |
Procédés d'induction de tolérance immunitaire à des facteurs de coagulation
|
|
MX2019006444A
(es)
|
2016-12-02 |
2019-10-30 |
Bioverativ Therapeutics Inc |
Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
|
|
KR20200018690A
(ko)
|
2017-06-22 |
2020-02-19 |
체에스엘 베링 렝나우 아게 |
절단된 vwf에 의한 fviii 면역원성의 조절
|
|
AU2018313921B2
(en)
|
2017-08-09 |
2024-12-19 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof
|
|
US10793327B2
(en)
|
2017-10-09 |
2020-10-06 |
Terumo Bct Biotechnologies, Llc |
Lyophilization container and method of using same
|
|
EP3746136A1
(en)
|
2018-02-01 |
2020-12-09 |
Bioverativ Therapeutics Inc. |
Use of lentiviral vectors expressing factor viii
|
|
EP3773517A1
(en)
|
2018-04-04 |
2021-02-17 |
Sigilon Therapeutics, Inc. |
Implantable particles and related methods
|
|
HUE071488T2
(hu)
|
2018-05-18 |
2025-09-28 |
Bioverativ Therapeutics Inc |
Hemofília A kezelésére szolgáló eljárások
|
|
US12091675B2
(en)
|
2018-07-16 |
2024-09-17 |
Takeda Pharmaceutical Company Limited |
Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
|
|
MX2021001599A
(es)
|
2018-08-09 |
2021-07-02 |
Bioverativ Therapeutics Inc |
Moleculas de acido nucleico y sus usos para la terapia genica no viral.
|
|
JP2022501373A
(ja)
*
|
2018-09-19 |
2022-01-06 |
セル マシン，インコーポレイテッド |
改善された第ｖｉｉｉ因子長期半減期凝固複合体に関連する方法および組成物
|
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
|
TWI851647B
(zh)
|
2019-01-16 |
2024-08-11 |
日商武田藥品工業股份有限公司 |
用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
|
|
MA54951A
(fr)
|
2019-02-15 |
2021-12-22 |
Bayer Healthcare Llc |
Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée
|
|
CN114127501B
(zh)
|
2019-03-14 |
2023-02-17 |
泰尔茂比司特生物技术有限公司 |
多部分冻干容器及使用方法
|
|
EP3736286A1
(en)
|
2019-05-09 |
2020-11-11 |
Biotest AG |
Single chain factor viii molecule
|
|
BR112021015776A2
(pt)
*
|
2019-06-05 |
2021-11-09 |
Bayer Healthcare Llc |
Edição de gene para hemofilia a com expressão de fator viii melhorada
|
|
WO2020257462A1
(en)
|
2019-06-19 |
2020-12-24 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii-fc for treating hemophilia and low bone mineral density
|
|
WO2021001522A1
(en)
|
2019-07-04 |
2021-01-07 |
CSL Behring Lengnau AG |
A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
|
|
WO2021067389A1
(en)
|
2019-09-30 |
2021-04-08 |
Bioverativ Therapeutics Inc. |
Lentiviral vector formulations
|
|
EP4058049A1
(en)
|
2019-11-11 |
2022-09-21 |
CSL Behring Lengnau AG |
Polypeptides for inducing tolerance to factor viii
|
|
JP2023506171A
(ja)
|
2019-12-12 |
2023-02-15 |
武田薬品工業株式会社 |
発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクターを使用する、血友病ａの遺伝子療法
|
|
JP7681268B2
(ja)
*
|
2020-03-30 |
2025-05-22 |
シスメックス株式会社 |
血液凝固活性の測定方法
|
|
CA3183557A1
(en)
|
2020-06-24 |
2021-12-30 |
Bioverativ Therapeutics Inc. |
Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
|
|
CN117858895A
(zh)
|
2021-06-14 |
2024-04-09 |
武田药品工业株式会社 |
使用表达增强的编码重组fviii变体的病毒载体的血友病a基因疗法
|
|
WO2023028456A1
(en)
|
2021-08-23 |
2023-03-02 |
Bioverativ Therapeutics Inc. |
Optimized factor viii genes
|
|
WO2023056331A1
(en)
|
2021-09-30 |
2023-04-06 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
|
EP4602155A1
(en)
|
2022-10-11 |
2025-08-20 |
Sigilon Therapeutics, Inc. |
Engineered cells and implantable elements for treatment of disease
|
|
TW202517669A
(zh)
|
2023-07-05 |
2025-05-01 |
日商武田藥品工業股份有限公司 |
用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體
|